Labroots invites you to the 4th Annual Event in the CRISPR Virtual Event Series! This event will continue the conversation of the abilities of CRISPR-based editing, next-gen editing tools, precision ...
The gene-editing stock had a rough run last year, and it's off to a rocky start in 2022. The stock's performance looks even more underwhelming in the context of the 26.9% growth that the S&P 500 index ...
CAMBRIDGE, Mass., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using ...
This study is led by Prof. Qunxin She (Shandong University) and Dr. Guanhua Yuan (Shandong University). The research group has constructed versatile genetic tools for Saccharolobus islandicus REY15A, ...
Medical innovations typically take 17 years from the time a lightbulb goes off in a scientist's head until the first person benefits. But every once in a while, an idea is so powerful and so profound ...
The stock's performance looks even more underwhelming in the context of the 26.9% growth that the S&P 500 index managed to post across the year's trading. While the benchmark index managed to post ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback